Array Instruments Market Report

The large number of patients awaiting a diagnosis of specific types of cancer, postnatal diseases and metabolic conditions, as well as research on the causes and treatments for such diseases, are what are driving the global market for array instruments. The most important and beneficial microarray usage for the diagnosis and prognosis of a variety of diseases, mostly cancer, has been disease diagnosis and detection. For instance, the American Cancer Society estimates that in 2023, 1.96 million new cancer cases and 609,820 cancer deaths were occurred in the United States. The increasing demand for minimally invasive surgeries is projected to boost market expansion. In minimally invasive surgeries, array instruments are utilised in order to provide surgeons with an excellent view of the operative field. Furthermore, these instruments are used to perform surgeries with a high degree of accuracy and precision. Annually, nearly 50 million surgeries are performed in the United States, while over 300 million major surgeries are conducted worldwide, according to the NIH. Growing demand for customised drugs and targeted therapies, together with an abundance of precise tools, will further drive prospects that will fuel the market expansion for a variety of instruments throughout the forecast period.

The lack of data analysis instruments in developing countries would limit the market's growth for several instruments throughout the forecast period. The major barrier to market development will be rising competition and emerging technologies. Cellular and tissue microarray technologies are still in the early stages and have their own limits. Tissue heterogeneity and high cost are two primary challenges limiting the adoption of tissue microarray. The high cost of array instruments restricts their application in regular practise in a number of countries. As a result, researchers are focusing on developing low-cost tissue microarrays. Certain disadvantages of using cellular microarrays have been linked to sensitivity. Additionally, automated data collection and image analysis are still in need of development.

Furthermore, the global array instruments market faces several restraints primarily due to the complexity and specialized skills required for operation and interpretation. Institutions often find the need for advanced training a significant barrier, which drives up both the total cost of ownership and operational complexities. Additionally, high-end array instruments demand substantial maintenance, with ongoing expenses for upkeep, repairs, and technical support. These recurring costs can discourage potential buyers from investing in or upgrading to newer models, impacting market growth and adoption rates.

The most conventional and commonly accepted technology is DNA microarray. As a result of greater accuracy and precision, as well as widespread adoption by end users, it accounts for the greatest proportion of the whole market. The introduction of DNA microarrays has accelerated gene expression, disease evaluation, drugs development and SNP analysis. Protein microarray, the second biggest and fastest developing technology, is particularly successful in finding protein-protein interactions, protein kinase substrates, and protein activities. Protein microarrays are frequently used in proteomics in protein expression profiling due to their high productivity, resolution, and sensitivity. Gene expression is the most important application market, followed by drugs discovery and diagnostics.

However, the scientists have introduced an innovative microfluidic chip produced to identify foodborne pathogens faster, more affordably, and more accurately. Using advanced 3D printing methods, this new chip uses light to detect numerous pathogens at once, enabling flexible manufacturing and tailoring to target particular pathogens.

In April 2024, Bio-Rad Laboratories joined forces with Oncocyte Corporation to advance transplant monitoring solutions. The partnership will leverage Bio-Rad’s Droplet Digital PCR (ddPCR) technology, including the QX600 ddPCR System, to enhance transplant monitoring assays. Bio-Rad will also invest in Oncocyte through a private equity placement and gain exclusive commercial rights in select regions, marking a significant move in the global array instruments market.

However, the QIAGEN announced on April, 2023 that their QIAstat-Dx syndromic testing solution would be available shortly in Japan along with a SARS-CoV-2 Respiratory Panel that's capable of detect over twenty pathogens from one patient's sample. Furthermore, in March 2023, Illumina Inc. has launched its innovative Illumina Complete Long Read technology, marking a significant advancement in the global array instruments market. This new high-performance human whole-genome sequencing assay, compatible with NovaSeq X Plus and NovaSeq 6000 systems, integrates long- and short-read data in a streamlined workflow with lower DNA input requirements.

North America dominates the global market for microarray instruments attributed to the majority of the major market players are based in North America, a significant amount of technological advancement is first introduced there. Europe is ranked second in the global market. Rising cancer and autoimmune disease incidents fuel the region's demand for disease diagnosis and treatment. Simplifying the process of analysis, increasing market consolidation and lowering the cost of equipment and reagents will result in fast adoption of microarray research in emerging countries. Developing nations in the Asia-Pacific region, Middle East, Latin America, and Africa will help to drive the global array instruments market forward. Advances in technology that result in improved specificity and sensitivity, as well as low cost and robustness, will enhance demand for microarray research, boosting market growth.